JBIO
$13.97
Jade Biosciences, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Induci...
Recent News
Jade Biosciences Touts “Best-in-Class” Autoimmune Antibodies, JADE101 Phase 1 Readout Nears
Jade Biosciences (NASDAQ:JBIO) outlined its strategy and near-term milestones at the Oppenheimer Life Sciences Conference, where CEO Tom Frohlich described the company’s focus on developing “best-in-class” monoclonal antibodies for autoimmune diseases using high-affinity binding and half-life extens
H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue
Jade Biosciences Inc. (NASDAQ:JBIO) is one of the overlooked growth stocks to buy. On January 7, H.C. Wainwright initiated coverage of Jade Biosciences with a Buy rating and $25 price target. The firm identified the company as being strategically positioned to secure a leadership role within the autoimmune market. The firm projects that JADE101, specifically […]
Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week
Key Insights Institutions' substantial holdings in Jade Biosciences implies that they have significant influence over...
Jade Biosciences (JBIO): Analyst Lauds Entry into Market
Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. On November 25, Clear Street analyst Kaveri Pohlman initiated coverage of Jade Biosciences, Inc. (NASDAQ:JBIO) stock with a Buy rating and $25 price target. In an investor note, the analyst underlined that there was conviction in JADE101, which […]
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect?
The mean of analysts' price targets for Jade Biosciences, Inc. (JBIO) points to a 65% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.